To our knowledge, only 4 cases of paraneoplastic pemphigus (PNP) associated with follicular dendritic cell sarcoma (FDCS) have been reported.1- 4 We describe herein a patient with PNP associated with FDCS with anti–laminin-332 autoantibodies.
Correspondence: Dr Sugiura, Department of Dermatology, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya, Japan, 466-8550 (firstname.lastname@example.org).
Conflict of Interest Disclosures: None reported.
Funding/Support: This study was supported in part by Grants-in-Aid for Scientific Research (C) 23591617 (Dr Sugiura) and (A) 23249058 (Dr Akiyama) from the Ministry of Education, Culture, Sports, Science and Technology of Japan.
Figure 1. Clinical and histopathological features of the patient. A, Erosions are observed on the whole body. B, Papillomatous hyperplasia on the tongue remains even after skin manifestations have improved owing to tumor resection and postoperative chemotherapy. C, Histopathologic evidence of erosion on the trunk (hematoxylin-eosin, original magnification ×400). D, Indirect immunofluorescence (IF) of normal human skin by circulating IgG of the patient at a titer of 1:160 (original magnification ×400). E, Indirect IF of 1M sodium chloride–split normal human skin by circulating IgG of the patient at a titer of 1:40 (original magnification ×200).
Figure 2. Immunoblot analyses of circulating autoantibodies in the patient's serum performed as described previously.1,5 A, Results of immunoblot analysis using epidermal extract: control paraneoplastic pemphigus (PNP) serum (lane 1) recognized the 210-kDa envoplakin and the 190-kDa periplakin, which were also detected by IgG (lane 2) and IgA (lane 3) antibodies in the serum of the present patient; control pemphigus vulgaris (PV) serum (lane 4) reacted with the 160-kDa desmoglein 1 and the 130-kDa desmoglein 3; control bullous pemphigoid (BP) serum (lane 5) reacted with the 180-kDa BP180. B, Results of immunoblot analysis using purified human laminin-332 before (lanes 2 and 3) and after (lanes 6 and 7) COP therapy was started (cyclophosphamide, vincristine [Oncovin; Genus Pharmaceuticals], and predonisone). A control antilaminin-332 mucous membrane (MMP) serum (lanes 1 and 5) reacted with the 165-kDa and 145-kDa α3 subunits, the 140-kDa β3 subunit, and the 105-kDa γ2 subunit. IgG antibodies in the serum of the present case (lanes 2 and 6) reacted with the 140-kDa β3 subunit and the 105-kDa γ2 subunit. No specific band was observed for IgA antibodies in the serum of the present patient (lanes 3 and 7) nor for IgG antibodies in serum from a healthy control (lanes 4 and 8).
Thank you for submitting a comment on this article. It will be reviewed by JAMA Dermatology editors. You will be notified when your comment has been published. Comments should not exceed 500 words of text and 10 references.
Do not submit personal medical questions or information that could identify a specific patient, questions about a particular case, or general inquiries to an author. Only content that has not been published, posted, or submitted elsewhere should be submitted. By submitting this Comment, you and any coauthors transfer copyright to the journal if your Comment is posted.
* = Required Field
Disclosure of Any Conflicts of Interest*
Indicate all relevant conflicts of interest of each author below, including all relevant financial interests, activities, and relationships within the past 3 years including, but not limited to, employment, affiliation, grants or funding, consultancies, honoraria or payment, speakers’ bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued. If all authors have none, check "No potential conflicts or relevant financial interests" in the box below. Please also indicate any funding received in support of this work. The information will be posted with your response.
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited: 1
Customize your page view by dragging & repositioning the boxes below.
More Listings atJAMACareerCenter.com >
Enter your username and email address. We'll send you a link to reset your password.
Enter your username and email address. We'll send instructions on how to reset your password to the email address we have on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.